Lyell Immunitumerma第二季度每股收益$（2.89）击败$（3.82）估计，销售额从同比13，000万美元下降8，000万美元

Lyell Immunopharma (NASDAQ: LYEL) reported quarterly losses of $(2.89) per share which beat the analyst consensus estimate of $(3.82) by 24.4 percent. This is a 19.5 percent increase over losses of $(3.59) per share from the same period last year. The company reported $8.000 thousand in sales this quarter. This is a 38.46 percent decrease over sales of $13.000 thousand the same period last year.